744P A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
Lee Jm(National Cancer Institute), Shannon MacLaughlan(University of Illinois Chicago), Daniela Matei(Northwestern University), Min Ji Song(City of Hope), Linda Brubaker(University of Colorado Health), B. Rimmel(Cedars-Sinai Medical Center), Ramez N. Eskander(University of California San Diego), Chrisann Kyi(Memorial Sloan Kettering Cancer Center), H. Williams(University of Arkansas Medical Center), L. Duska(University of Virginia Medical Center), Fernanda Musa(Swedish Medical Center), R.L. Coleman(The US Oncology Network), B.M. Slomovitz(Mount Sinai Medical Center), Eric Gamelin(C4 Therapeutics (United States)), J-M. Cuillerot(New England Research Institutes), M.M. Phadnis(C4 Therapeutics (United States)), Brendan J. Guercio(University of Rochester Medical Center), S. Crafton(Western Pennsylvania Hospital), P.A. Konstantinopoulos(Dana-Farber Cancer Institute)
Cited by 2Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis